LAS VEGAS, April 21 Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ), is focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally. Its CEO and co-founder, Matthew Schissler, in an interview with analyst Francis Gaskins, said a focus this year is top-line revenue growth.
The entire interview is available at http://gaskinsco.com/cbai-4-20-10.mp3
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
-- The announcement that the Cord Blood America is seeking to purchase controlling interest in a major, profitable South American stem cell company could increase revenue by $1.0 to $1.5 million in the next 12 month time period. -- The purchase of a stem cell company in Germany, previously announced, could add up to $1 million in revenues also in the next 12 months. -- The agreement to collect placentas for a world renowned tissue bank, announced this week, could add up to one million dollars in revenues annually and significantly diversifies the Company's revenue stream. -- Cord Blood America recently visited China where its new facility, in partnership with a Chinese pharmaceutical company, will have storage facilities ten times the size of Cord Blood America's new Las Vegas laboratory, which is believed to be the largest of its kind in the U.S. Operations are scheduled to begin in 2011.
SOURCE Cord Blood America, Inc.